Navigation Links
ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
Date:12/12/2012

EXTON, Pa., Dec. 12, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the launch of a new unbranded campaign focusing on moments lost to hereditary angioedema (HAE) attacks to raise awareness among physicians of the emotional and psychological burden of HAE on patients' lives. HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of a human plasma protein called C1 inhibitor. People living with HAE experience physical manifestations of attacks including, swelling and pain, but much of the true burden lies in the emotional and psychological implications for patients that greatly impact the quality of their life. Visit http://www.momentsmissed.com to find out more about the emotional burden of HAE.

HAE can have a tremendous impact on a patients' mental health, daily life, and future plans. HAE attacks are highly variable and unpredictable, and many people living with HAE experience multiple attacks per month. Many patients struggle with fear of the next attack, causing a devastating psychological impact including anxiety, depression, and isolation. Approximately 50 percent of patients experience a laryngeal attack, and nearly all live in fear of having such an attack.

"Through this campaign we hope to illustrate that HAE is not just an acute clinical condition, but can also be an emotional and psychological burden to patients," said Frank Nazzario, ViroPharma's associate director, marketing. "HAE is a life altering disease that interferes with work, school, travel and social life. ViroPharma created this campaign to give a voice to patients who bear the emotional burden of HAE and to raise awareness of the moments that are missed as a result of this disease."  

About Hereditary Angioedema (HAE)
HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and at least 10,000 people in the European Union.

For more information on HAE, visit the U.S. HAE Association's website at www.haea.org and the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at www.haei.org.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency, cytomegalovirus (CMV); and recurrent C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures, adrenal insufficiency and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
11. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... disease and heart failure, today announced that it intends to ... stock in an underwritten public offering.  The offering is subject ... assurance as to whether or when the offering may be ... the offering.   --> --> ...
(Date:2/9/2016)... , February 9, 2016 ... company focused on developing products for Regenerative Medicine, Neurology ... a featured presenting company at Source Capital Group,s 2016 ... February 10-11, 2016 in New York City ... Wednesday, February 10, 2016 at 12:30 pm by ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... ... Shark Finds and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro are pleased to ... patented product that has solved some of the basic problems golfers have faced since the ... right after a rain shower, might understand the struggle of placing the club down for ...
(Date:2/8/2016)... ... 08, 2016 , ... The Federal Laboratory Consortium for Technology ... site houses a wealth of federal resources that businesses can leverage to further ... transfer (T2). As a network of over 300 federal laboratories, the FLC’s mission ...
(Date:2/8/2016)... ... 2016 , ... Stephanie Hebert Insurance Agency, serving families of ... charity campaign. As part of their ongoing community involvement program, funds are now ... children deserve a voice, and in the spirit of neighbors helping neighbors in ...
(Date:2/8/2016)... Alexandria, Minn. (PRWEB) , ... February 08, 2016 ... ... introduces the BantamPro L top-load case packer for pouches, bags, and flow wrapped ... designed to help co-packers and specialty product manufacturers step up to semi-automatic or ...
(Date:2/8/2016)... Island, SC (PRWEB) , ... February 08, 2016 , ... ... surrounding areas with a vital new community enrichment program, has teamed up with Citizens ... women and children suffering from intimate abuse. To support all those victimized by the ...
Breaking Medicine News(10 mins):